American Journal of Clinical Dermatology Submission Guide
A source-checked AJCD guide for clinical dermatology fit, article type, structured abstracts, key points, patient-facing context, declarations, and final checks.
Readiness scan
Find out if this manuscript is ready to submit.
Run the Free Readiness Scan before you submit. Catch the issues editors reject on first read.
How to approach American Journal of Clinical Dermatology
Use the submission guide like a working checklist. The goal is to make fit, package completeness, and cover-letter framing obvious before you open the portal.
Stage | What to check |
|---|---|
1. Scope | Confirm clinical-dermatology and article-type fit |
2. Package | Verify current Springer submission requirements |
3. Cover letter | Submit through the current Editorial Manager route |
Quick answer: Submit to the American Journal of Clinical Dermatology when the paper has a clear clinical dermatology owner: diagnosis, treatment, safety, disease management, patient outcome, or a clinically useful synthesis. A molecular or materials result with a possible skin application is not enough unless the clinical bridge is already part of the evidence.
Evidence basis: We checked the current American Journal of Clinical Dermatology page, the journal-specific instructions for authors, and linked Springer Nature guidance on August 21, 2026. Requirements and article-format facts are sourced. The decision tools are Manusights editorial judgment.
Evidence boundary: This guide cannot predict acceptance or an editorial decision. Treat a review without a reproducible synthesis method, an original study without a clinically useful decision, or incomplete declarations as a stop signal and route the manuscript elsewhere when clinical management does not own the contribution.
Submission route: Use the current American Journal of Clinical Dermatology Editorial Manager portal linked by Springer Nature. Instructions and fees can change, so recheck the live article type, review route, word and display limits, declarations, and portal before upload. Public sources cannot predict a case-level decision.
Check whether the clinical claim and evidence still point to the same dermatology decision.
From our manuscript review practice
AJCD fit is strongest when a dermatologist can see the clinical decision, patient group, evidence, and treatment or diagnostic boundary on the first page.
Does AJCD own the manuscript?
Question | Strong fit signal | Warning sign |
|---|---|---|
What dermatologist or patient decision changes? | Diagnosis, treatment selection, monitoring, safety, prognosis, or care pathway is explicit | Skin disease is only the application example |
Which patient group is represented? | Disease definition, severity, phenotype, age, setting, and treatment context are clear | “Patients with dermatologic disease” is treated as homogeneous |
What evidence carries the claim? | Design, comparator, outcome, harms, and uncertainty support the conclusion | Surrogate or laboratory evidence becomes clinical efficacy |
What should not be inferred? | Population, follow-up, rare harms, confounding, and generalizability limits are visible | Limitations are detached from the clinical recommendation |
Choose the article shape before drafting
AJCD publishes clinically focused reviews and original research. Confirm the exact live article type and limits before writing because a narrative review, systematic review, clinical study, and commentary have different evidence jobs.
Article shape | What it must deliver | Common mismatch |
|---|---|---|
Original clinical research | A defined patient question, valid design, outcomes, harms, and clinical interpretation | A mechanistic signal is presented as practice-ready |
Systematic review or meta-analysis | Reproducible search, eligibility, appraisal, synthesis, heterogeneity, and certainty | A broad narrative is labeled systematic |
Narrative clinical review | A transparent, useful synthesis organized around real clinical decisions | A textbook overview with no decision framework |
Treatment or safety review | Comparative benefits, harms, patient selection, monitoring, and evidence gaps | One product or class is described without alternatives |
Build the clinical evidence map
Layer | Evidence to put near the claim | Risk when missing |
|---|---|---|
Population | Diagnostic criteria, phenotype, severity, skin type, age, comorbidity, and setting | The result is generalized across different disease presentations |
Intervention or exposure | Dose, duration, co-interventions, adherence, and comparator | Treatment effect cannot be interpreted |
Outcome | Clinical meaning, measurement validity, timing, absolute effect, and uncertainty | Statistical significance substitutes for benefit |
Safety | Adverse events, ascertainment, follow-up, and rare-event limitation | Efficacy is separated from the patient tradeoff |
Applicability | Access, burden, monitoring, equity, and patient preference | Recommendation assumes an ideal care setting |
Worked example
A weak treatment paper says a therapy significantly improved disease scores. A stronger clinical account names baseline severity, comparator, absolute improvement, responder threshold, time point, discontinuation, adverse events, and the patient group for whom the tradeoff is plausible.
Prepare the abstract, key points, and plain-language summary
The current journal-specific instructions ask original research articles to use a structured abstract. Make each heading do a distinct job: purpose, methods, results, and conclusion should not repeat one another.
The instructions also ask for two or three key-point statements. Use them to state what was known, what the paper adds, and what decision or uncertainty changes. Do not turn them into marketing claims.
An optional plain-language summary of up to 250 words is described in the current instructions. Explain:
- the patient or clinical problem;
- what the study or review examined;
- the main result in ordinary language;
- the most important limitation;
- what patients or clinicians can and cannot conclude.
Reporting, ethics, and declarations
Use the reporting guideline that matches the design: CONSORT, STROBE, PRISMA, STARD, TRIPOD, CARE, or another appropriate EQUATOR route. For image-based or AI studies, describe datasets, labeling, reference standards, skin-tone representation, external validation, and failure cases.
For human research, include approval, consent, privacy, and trial registration where applicable. Clinical images can identify patients even when names are removed; follow the live consent requirements.
Prepare funding, conflicts, author contributions, data availability, ethics, consent, prior publication, and related-manuscript disclosures. The current journal instructions include a declarations section; keep each statement consistent with the submission fields.
Make figures clinically useful
Clinical images should have consistent lighting, scale, labeling, timing, and consent. Do not use dramatic “before and after” selection without explaining how images were chosen. For pathology or microscopy, name stain, magnification, scale, and the diagnostic feature the reader should see.
Tables should help a clinician compare populations, interventions, outcomes, harms, and certainty. A long list of studies is less useful than a decision table that exposes why results differ.
Calibrate against recent AJCD papers
Read several recent American Journal of Clinical Dermatology records before fixing the article's final shape. Examples include 10.1007/s40257-025-00963-7, 10.1007/s40257-023-00809-0, and 10.1007/s40257-020-00550-y. Their practical lesson is variation: different clinical questions require different balances of evidence synthesis, patient context, safety, and actionability.
Use them to audit, not imitate. For your paper, write one sentence each for the patient population, the clinical choice, the benefit evidence, the harm or burden, and the residual uncertainty. Those five statements should be easy to locate in the abstract, opening section, and conclusion. If the clinical recommendation is easier to find than its evidence boundary, the narrative is too promotional. If disease background occupies more space than the decision, the reader job is still buried.
Common failure patterns in AJCD submissions
In our pre-submission review work, the most common weakness is a clinical recommendation that outruns the represented patients and follow-up. This is Manusights editorial observation, not access to private AJCD decisions.
Skin phenotype and population are underspecified. Restore the patient characteristics that affect diagnosis, response, or safety.
A surrogate becomes a patient outcome. Separate biomarker, lesion score, symptom, quality of life, recurrence, and long-term safety.
Images carry more persuasion than evidence. Explain selection, timing, measurement, and the full analysis.
A review lists therapies but never compares decisions. Organize evidence around patient selection, benefit, harm, monitoring, access, and uncertainty.
Readiness check
Run the scan against the requirements while they're in front of you.
See score, top issues, and journal-fit signals before you submit.
Compare nearby destinations
Venue | Stronger owner when | Decisive check | Why AJCD may be wrong |
|---|---|---|---|
Journal of the American Academy of Dermatology | Broad clinical dermatology practice and a large specialty audience own the result | Does the paper address a general specialty practice decision? | The article is primarily a focused evidence synthesis |
JAMA Dermatology | The study has exceptional clinical, methodological, or policy consequence | Does the result travel beyond one dermatology decision? | The paper is useful but narrower in reach |
British Journal of Dermatology | Broad dermatologic science and clinical research, including strong mechanistic links, dominate | Does the biology share ownership with the clinical finding? | The article is chiefly a clinically focused review |
Experimental Dermatology | Basic or translational skin biology owns the paper | Is mechanism more important than patient management? | The central job is a patient-care decision |
Final checklist
- [ ] Confirm the live article type and limits.
- [ ] Align title, abstract, key points, figures, tables, and conclusion.
- [ ] Use the correct reporting checklist.
- [ ] Verify clinical images, consent, accessibility, and captions.
- [ ] Report absolute effects, harms, uncertainty, and follow-up.
- [ ] Complete declarations and data availability.
- [ ] Recheck every source, number, file, and portal field.
What happens after submission
AJCD does not promise a case-specific timeline, so use this as a four-stage decision map rather than a prediction.
- Package intake: the journal checks article type, files, title page, authorship, declarations, and the live submission guidelines.
- Editorial assessment: an editor tests whether the paper changes an evidence-based dermatology or patient-management decision.
- Peer review: suitable manuscripts move to reviewers who can inspect synthesis methods or original-study methods, figures, reporting, and clinical interpretation.
- Revision or decision: authors reconcile every report with the abstract, key points, evidence tables, declarations, and conclusions before the next decision.
If the clinical decision is still hard to find, run a final dermatology evidence review.
Submit if
- A clinical dermatology decision owns the paper.
- Population, comparator, outcome, harms, and uncertainty are clear.
- The article type and reporting guideline match the work.
- Key points and any plain-language summary remain accurate and restrained.
- Ethics, consent, privacy, data, funding, conflicts, and contributions are complete.
Think twice if
- Clinical relevance is projected from preclinical evidence.
- Patient diversity or skin phenotype needed for interpretation is missing.
- A short follow-up supports a durable safety or efficacy claim.
- A review catalogs studies without helping readers choose.
Frequently asked questions
What kind of paper fits the American Journal of Clinical Dermatology?
The journal publishes clinically focused dermatology research and reviews. The patient, diagnostic, therapeutic, safety, or practice consequence should remain central.
Does AJCD require key points?
The current journal-specific instructions ask for two or three short key-point statements.
Can I include a plain-language summary?
The current instructions describe an optional plain-language summary of up to 250 words.
Where do I submit?
Use the current submission route linked from the Springer Nature journal page.
Official sources accessed August 21, 2026.
- American Journal of Clinical Dermatology journal page, Springer Nature.
- American Journal of Clinical Dermatology instructions for authors, Springer Nature.
- EQUATOR reporting guideline library, EQUATOR Network.
- AJCD Editorial Manager submission portal, Springer Nature.
Frequently asked questions
The journal publishes clinically focused dermatology research and reviews. The patient, diagnostic, therapeutic, safety, or practice consequence should remain central.
The current journal-specific instructions ask for two or three short key-point statements. Verify the live instructions because presentation requirements can change.
The current instructions describe an optional plain-language summary of up to 250 words. Use it to explain the clinical question, result, and limit without promotional language.
Use the current submission route linked from the Springer Nature journal page and verify article type, review model, declarations, files, and fees before upload.
Before you upload
Choose the next useful decision step first.
Move from this article into the next decision-support step. The scan works best once the journal and submission plan are clearer.
Use the scan once the manuscript and target journal are concrete enough to evaluate.
Anthropic Privacy Partner. Your manuscript is never used to train any model.